Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients - PubMed (original) (raw)
Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients
M Bajaj et al. Int J Obes Relat Metab Disord. 2004 Jun.
Abstract
Objectives: To study the effect of pioglitazone (PIO) on plasma resistin concentration, endogenous glucose production (EGP), and hepatic fat content (HFC) in patients with type II diabetes (T2DM).
Subjects: A total of 13 T2DM patients (age=51+/-2 y, BMI=29.7+/-1.1 kg/m(2), HbA(1c)=8.0+/-0.5%).
Methods: HFC (magnetic resonance spectroscopy) and basal plasma resistin concentration were quantitated before and after PIO treatment (45 mg/day) for 16 weeks. Subjects received a 3 h euglycemic insulin (100 mU/m(2)/min) clamp with 3-[(3)H] glucose to determine rates of EGP and tissue glucose disappearance (Rd) before and after PIO.
Results: PIO reduced fasting plasma glucose (10.3+/-0.7 to 7.6+/-0.6 mmol/l, P<0.001) and HbA(1c) (8.0+/-0.4 to 6.8+/-0.3%, P<0.001) despite increased body weight (83.2+/-3.4 to 86.3+/-3.4 kg, P<0.001). PIO improved Rd (4.9+/-0.4 to 6.6+/-0.5 mg/kg/min, P<0.005) and reduced EGP (0.22+/-0.04 to 0.06+/-0.02 mg/kg/min, P<0.01) during the insulin clamp. Following PIO, HFC decreased from 21.1+/-3.5 to 11.2+/-2.1% (P<0.005), and plasma resistin decreased from 5.3+/-0.6 to 3.5+/-0.3 ng/ml (P<0.01). Plasma resistin concentration correlated positively with HFC before (r=0.58, P<0.05) and after (r=0.55, P<0.05) PIO treatment. Taken collectively, plasma resistin concentration, before and after PIO treatment, correlated positively with hepatic fat content (r=0.66, P<0.001) and EGP during the insulin clamp (r=0.41, P<0.05). However, the plasma resistin concentration did not correlate with whole body glucose disposal (Rd) during the insulin clamp either before (r=-0.18, P=NS) or after (r=-0.13, P=NS) PIO treatment.
Conclusions: PIO treatment in T2DM causes a significant decrease in plasma resistin concentration. The decrease in plasma resistin is positively correlated with the decrease in hepatic fat content and improvement in hepatic insulin sensitivity.
Similar articles
- Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA. Bajaj M, et al. J Clin Endocrinol Metab. 2004 Jan;89(1):200-6. doi: 10.1210/jc.2003-031315. J Clin Endocrinol Metab. 2004. PMID: 14715850 - Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Miyazaki Y, et al. J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9. doi: 10.1210/jc.2004-0190. J Clin Endocrinol Metab. 2004. PMID: 15356026 Clinical Trial. - Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA. Miyazaki Y, et al. J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91. doi: 10.1210/jcem.87.6.8567. J Clin Endocrinol Metab. 2002. PMID: 12050251 - Cellular mechanisms of insulin resistance in humans.
Shulman GI. Shulman GI. Am J Cardiol. 1999 Jul 8;84(1A):3J-10J. doi: 10.1016/s0002-9149(99)00350-1. Am J Cardiol. 1999. PMID: 10418851 Review. - Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis.
Donga E, Dekkers OM, Corssmit EP, Romijn JA. Donga E, et al. Eur J Endocrinol. 2015 Jul;173(1):101-9. doi: 10.1530/EJE-14-0911. Epub 2015 Apr 21. Eur J Endocrinol. 2015. PMID: 25899581 Review.
Cited by
- Role of resistin in cardiac contractility and hypertrophy.
Kim M, Oh JK, Sakata S, Liang I, Park W, Hajjar RJ, Lebeche D. Kim M, et al. J Mol Cell Cardiol. 2008 Aug;45(2):270-80. doi: 10.1016/j.yjmcc.2008.05.006. Epub 2008 May 20. J Mol Cell Cardiol. 2008. PMID: 18597775 Free PMC article. - Adipose Tissue: A Metabolic Regulator. Potential Implications for the Metabolic Outcome of Subjects Born Small for Gestational Age (SGA).
Maiorana A, Del Bianco C, Cianfarani S. Maiorana A, et al. Rev Diabet Stud. 2007 Fall;4(3):134-46. doi: 10.1900/RDS.2007.4.134. Epub 2007 Nov 10. Rev Diabet Stud. 2007. PMID: 18084671 Free PMC article. - Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies.
Deeg MA, Tan MH. Deeg MA, et al. PPAR Res. 2008;2008:520465. doi: 10.1155/2008/520465. PPAR Res. 2008. PMID: 18769492 Free PMC article. - Resistin expression correlates with steatohepatitis in morbidly obese patients.
Edwards CR, Hindle AK, Latham PS, Fu SW, Brody FJ. Edwards CR, et al. Surg Endosc. 2013 Apr;27(4):1310-4. doi: 10.1007/s00464-012-2603-y. Epub 2012 Dec 12. Surg Endosc. 2013. PMID: 23233000 - A role for calcium in resistin transcriptional activation in diabetic hearts.
Singh R, Moreno P, Hajjar RJ, Lebeche D. Singh R, et al. Sci Rep. 2018 Oct 23;8(1):15633. doi: 10.1038/s41598-018-34112-4. Sci Rep. 2018. PMID: 30353146 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous